Replies to post #121890 on Anavex Life Sciences Corp (AVXL)

[falconer66a]

Sigma-1 Receptor Agonists for Other Human Diseases

Might homeostasis lead to proper protein folding in the pancreas to allow a drug similar to or A2-73 itself to allow the Type One diabetic to produce his/her own insulin in the proper measure daily with an oral dose of the homeostasis drug?

What might restrict organelle function support (generalized “homeostasis”) to a) merely Anavex 2-73, and b) only in neurons? There is a considerable prospect that other sigma-one receptor agonist molecules might be able to restore function to cells other than just neurons, including insulinogenic cells in the diabetic pancreas.

Look at the molecules already in the Anavex pipeline, and the diseases and conditions for which there are preclinical indications of treatment efficacies. Four different molecules, targeted at Rett syndrome, Alzheimer's disease, Parkinson's disease, Infantile spasms, Fragile, Angelman's, Frontotemporal Dementia, Depression, Stroke, Visceral pain, Acute & Neuropathic pain, and Pancreatic cancer.

Quite different diseases, very different involved cells.

Certainly researchers today are dosing diseased lab rats and mice with various analogues of the Anavex molecules. No good reason to believe therapeutic results would be constrained only to the dementias Anavex 2-73 is presently aimed at.

At the discovery of penicillin there was no immediate prospect of a multitude of antibiotics treating a diversity of infectious diseases. The discovery, development, and applications of new Anavex analogues will be an interesting story to watch. Will be some of the later chapters in the unfolding Anavex story, some years from now.

[A safe harbor caution. Use none of the above for the basis of any buy or sell decision regarding AVXL shares. The information is informed speculation, unsuitable as investment due diligence.]